Report
Louis-Clément AZAIS d'UHART
EUR 112.46 For Business Accounts Only

Analyse court terme - PFIZER INC : Le support est enfoncé.

Lors de notre dernière analyse court terme (13/10/2016), nous avions opté pour un avis négatif.
Nous restons négatif avec un objectif à 31,5 $ et un niveau d'invalidation à 33,5 $.
La tendance haussière est peut-être en train de se retourner à la baisse.
Arguments :
- Le...
Underlying
Pfizer Inc.

Pfizer is a research-based biopharmaceutical company. The company is engaged in discovering, developing, manufacturing and distributing of healthcare products, including medicines and vaccines. The company manages its commercial operations through three businesses: Pfizer Biopharmaceuticals Group, which includes Oncology, Inflammation and Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine business units, as well as a hospital business unit; Upjohn, which includes the company's solid oral dose brands such as Lyrica, Lipitor, Norvasc, Celebrex, Viagra, and certain generic medicines; and Consumer Healthcare, which is an over-the-counter medicines business.

Provider
Day By Day
Day By Day

​​DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.

Analysts
Louis-Clément AZAIS d'UHART

Other Reports on these Companies
Other Reports from Day By Day

ResearchPool Subscriptions

Get the most out of your insights

Get in touch